Home › Pfizer And Synthon Enter Into U.S. Commercialization Agreement For Potential Generic Treatment Of Multiple Sclerosis
 

Keywords :   


Pfizer And Synthon Enter Into U.S. Commercialization Agreement For Potential Generic Treatment Of Multiple Sclerosis

2015-08-05 07:09:59| drugdiscoveryonline Home Page

Pfizer Inc. and Synthon, an international pharmaceutical company specializing in the development of complex generic medicines, recently announced they have entered into an agreement whereby Pfizer has acquired the exclusive commercialization rights in the United States to glatiramer acetate, a potential generic version of the originator medicine Copaxone for the treatment of relapsing remitting multiple sclerosis (RRMS)

Tags: of enter agreement multiple

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Unpaid carers being forced to repay 250m to DWP
18.05Weekly Recap: Hempel, Axalta, KANSAI HELIOS Top This Weeks Stories
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
More »